Compare Jumia Technologies AG - ADR (JMIA) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Nuvalent Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.33 (market cap $783.99M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 12.5× Jumia Technologies AG - ADR's market cap, and Nuvalent Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| JMIA | NUVL | |
|---|---|---|
Market Cap | $783.99M | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $14.60 | $123.96 |
52-Week Low | $4.45 | $72.16 |
Enterprise Value | $731.09M | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.36, down 2.15% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, targeting 2027 profitability. Analyst sentiment remains positive with 71% buy ratings despite recent earnings misses. Recent news highlights strong Q1 2026 performance and strategic board appointments.
JMIA presents a high-risk opportunity with significant upside potential if profitability targets are met. The stock faces execution risks in African e-commerce expansion and persistent negative cash flow, but strong revenue growth and analyst support suggest potential for recovery if the 2027 breakeven timeline is achieved.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
